News

Net profit of FDC rose 167.39% to Rs 103.40 crore in the quarter ended March 2026 as against Rs 38.67 crore during the previous quarter ended March 2025. Sales rose 18.89% to Rs 584.79 crore in the quarter ended March 2026 as against Rs 491.89 crore during the previous quarter ended March 2025.For the full year,net profit rose 5.48% to Rs 281.42 crore in the year ended March 2026 as against Rs 266.79 crore during the previous year ended March 2025. Sales rose 2.98% to Rs 2170.93 crore in the year ended March 2026 as against Rs 2108.12 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales584.79491.89 19 2170.932108.12 3 OPM %18.1910.97 -15.9415.41 - PBDT154.7068.87 125 454.63410.95 11 PBT140.3553.31 163 395.39357.22 11 NP103.4038.67 167 281.42266.79 5 Powered by Capital Market - Live News

Net profit of FDC rose 122.04% to Rs 107.07 crore in the quarter ended March 2026 as against Rs 48.22 crore during the previous quarter ended March 2025. Sales rose 17.09% to Rs 564.36 crore in the quarter ended March 2026 as against Rs 482.00 crore during the previous quarter ended March 2025.For the full year,net profit rose 4.49% to Rs 285.92 crore in the year ended March 2026 as against Rs 273.63 crore during the previous year ended March 2025. Sales rose 2.72% to Rs 2126.33 crore in the year ended March 2026 as against Rs 2070.11 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales564.36482.00 17 2126.332070.11 3 OPM %19.7810.96 -16.5615.47 - PBDT157.2783.08 89 458.25421.29 9 PBT142.9667.55 112 399.15367.68 9 NP107.0748.22 122 285.92273.63 4 Powered by Capital Market - Live News

FDC will hold a meeting of the Board of Directors of the Company on 27 May 2026.

FDC has granted ANDA approval by United States Food and Drug Administration (U.S.FDA), for Cefixime for Oral Suspension USP, 100 mg / 5 mL and 200 mg/ 5 mL.

Net profit of FDC declined 23.60% to Rs 28.30 crore in the quarter ended December 2025 as against Rs 37.04 crore during the previous quarter ended December 2024. Sales rose 0.13% to Rs 464.71 crore in the quarter ended December 2025 as against Rs 464.11 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales464.71464.11 0 OPM %11.2510.05 - PBDT71.9664.53 12 PBT57.1751.18 12 NP28.3037.04 -24 Powered by Capital Market - Live News